Loading
AccSalus uses computer models to design new drug molecules; its first cancer medicine, a tablet that blocks several growth-signalling proteins, is about to enter a first trial in advanced solid tumours.
AccSalus (the website names AccSalus Scitech Inc., with an office at 116 East 78th Street, New York; the registry sponsor is AccSalus Biosciences, Inc.) describes itself as designing drug candidates with AI-driven chemical design, including for properties such as crossing the blood-brain barrier. Its registered programme is ACC-1898, which the registry describes as an oral multi-kinase tyrosine kinase inhibitor, in a phase 1 dose-finding study in advanced solid tumours including hepatocellular carcinoma, renal cell carcinoma and medullary and differentiated thyroid cancer (NCT07252661), not yet recruiting, with an estimated start in January 2027. Its first registered cancer trial, NCT07252661, was posted on ClinicalTrials.gov in November 2025.
Shares AI-driven drug & target discovery, Small-molecule kinase inhibitors.
Shares AI-driven drug & target discovery, Small-molecule kinase inhibitors.
Shares AI-driven drug & target discovery, Small-molecule kinase inhibitors.
Shares AI-driven drug & target discovery, Small-molecule kinase inhibitors.
Shares AI-driven drug & target discovery, Small-molecule kinase inhibitors.
Shares AI-driven drug & target discovery, Small-molecule kinase inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/